Evaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Authors:
- Hayley BarnesHBHayley Barnes
- David P. NadebaumDNDavid P. Nadebaum
- Daniel NiewodowskiDNDaniel Niewodowski
- J. K. KhooJKJ. K. Khoo
- Yuan Z. LimYLYuan Z. Lim
- Bradley J. GardinerBGBradley J. Gardiner
- Tiffany LinTLTiffany Lin
- Martin H. CherkMCMartin H. Cherk
- Miranda SiemienowiczMSMiranda Siemienowicz
- Jyotika D. PrasadJPJyotika D. Prasad
- Ryan HoyRHRyan Hoy
Open Access
- 4 June 2026
- journal article
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Abstract
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.Keywords
Funding Information
- WorkSafe Victoria
This publication has 28 references indexed in Scilit:
- High metabolic activity in positron emission tomography and systemic inflammation occurring years after exposure cessation in engineered stone silicosisScientific Reports, 2025
- Silicosis, Sarcoidosis, or Both? Rethinking Disease Labels in Light of Co‐OccurrenceAmerican Journal of Industrial Medicine, 2025
- Silicosarcoidosis: Histologic and Clinical Features of an Occupational Granulomatous DiseaseAmerican Journal of Industrial Medicine, 2025
- Silicosis Among Immigrant Engineered Stone (Quartz) Countertop Fabrication Workers in CaliforniaJAMA Internal Medicine, 2023
- Predictors of health-related quality of life among semi-precious stone mineworkers exposed to silica dustInternational Archives of Occupational and Environmental Health, 2021
- Artificial Stone SilicosisChest, 2020
- Inflammasome activation and regulation: toward a better understanding of complex mechanismsCell Discovery, 2020
- Artificial stone‐associated silicosis: clinical‐pathological‐radiological correlates of diseaseRespirology Case Reports, 2019
- Natural course of silicosis in dust-exposed workersCurrent Medical Science, 2006
- Angular and fibrous particles in lung in relation to silica-induced diseases.International Archives of Occupational and Environmental Health, 1998